The decision comes after the company provided information explaining the delay of registration of its stock emission on the bourse – the reason is the delay of the registration of the company's capital increase with the Commercial register.
The company's plans on floating the emission have not changed and it guarantees that all legal requirements related to it will be met.
Tchaikapharma's core activities include production, packagaing (primary and secondary), marketing and promotion of medicines.
The company focuses especially on medicines of the cardiovascular system, diabetes and central nervous system.
The company currently operates on the home market but one of its long-term priorities isexport oriented production.
Tchaikapharma High Quality Medicines' principal shareholder is Tihomir Kamenov controlling 96% of its capital.